Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

Indication Sought for Breakthrough Pain Associated with Chronic Pain

Conditions in Patients Who are Already Taking Opioid Medications

Around-the-Clock

FRAZER, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid tolerant patients with chronic pain conditions. Breakthrough pain is characterized by its rapid onset, moderate- to-severe intensity, and relatively short duration. According to a study published in the August 2006 issue of The Journal of Pain, up to 74 percent of patients with non-cancer chronic pain conditions treated for persistent pain, such as chronic low back and chronic neuropathic pain, will experience breakthrough pain. Currently FENTORA is approved for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent pain.

"The clinical trials supporting this submission mark the first time a pain medication has been evaluated as a treatment for breakthrough pain associated with serious chronic pain conditions other than cancer," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We look forward to working with FDA to broaden the use of FENTORA to opioid tolerant patients with unresolved debilitating breakthrough pain."

The FENTORA sNDA includes data from three randomized, placebo-controlled clinical trials and one long-term open-label safety study with a total of 941 opioid tolerant patients. The patients in the FENTORA sNDA trials were treated for up to 18 months and had a broad range of underlying chronic pain conditions, including chronic low back and chronic neuropathic pain. In the randomiz
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... US demand for specialty biocides is forecast to ... 2018. In volume terms, demand is projected to increase ... the same period. A strong rebound in construction expenditures ... and paint and coatings markets, while growth in consumer ...
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "Global and Chinese Microcrystalline Cellulose Industry Report ... The Global and Chinese Microcrystalline Cellulose Industry Report 2014 ... state of the global microcrystalline cellulose industry with a ... provides a basic overview of the industry including definitions, ...
(Date:9/22/2014)... FierceBiotech today announced its annual “Fierce ... of 2014. FierceBiotech editors John Carroll and Damian ... winners. Those selected are identified as some of ... , "It's always a lot of fun ... companies," said Carroll. "This year in particular you'll find ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... Last night, as I watched my brothers set off marginally ... checked e-mail since Sunday morning, and my mobile phone was ... of July weekend, the mid-summer respite, and I felt anything ... hours even over a holiday weekend comes with ...
... as businesses seek to protect and enhance the value ... result of the business' products and services. Each year, ... many of them for federal trademark registration. Indeed, applications ... good leading indicator of economic conditions (a steep drop ...
... Madison, Wis. The National Institutes of ... a $4 million Fast-Track SBIR grant from the ... Diseases. , ,Under this grant, Stratatech will work ... substitute with enhanced antimicrobial and angiogenetic properties for ...
Cached Biology Technology:Declaring independence from technology (sort of) 2Declaring independence from technology (sort of) 3Why file for trademark protection? 2Why file for trademark protection? 3Why file for trademark protection? 4
(Date:9/22/2014)... in recent years has been identified as the plant,s ... aroma also summons beneficial insects to the rescue. , ... the environment via the emission of volatile organic compounds, ... wasps to come to the plant that is being ... Dr. Michael Kolomiets, Texas A&M AgriLife Research plant pathologist ...
(Date:9/22/2014)... in a plant,s biological clock one that modulates ... , Transcription factors, or genetic switches, drive gene expression ... light, rain, soil quality, or even animals grazing on ... one, called FBH1, that reacts to temperature tweaking ... keeping it on a consistent track. , "Temperature helps ...
(Date:9/22/2014)... CITY (September 22, 2014)The Brain & Behavior ... award of NARSAD Young Investigator Grants valued ... of the world,s most promising young scientists. ... groundbreaking neurobiological research will seek to identify ... for psychiatric disorders that affect one in ...
Breaking Biology News(10 mins):Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3Genetic switch regulates a plant's internal clock based on temperature 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2
... for cystic fibrosis, HIV-fighting ,Trojan horses, new pharmaceuticals from ... to discover medications of the future. ,On 24 August, ... an international conference in Gothenburg, Sweden. In ... to investigate, and eventually control, the behavior of cells. ...
... researcher is challenging health standards that consider nitrates and ... research suggests that although there are negative health effects ... nitrates in groundwater, nitrates and nitrites -- as they ... Nitrate and nitrite are naturally occurring ions associated ...
... visceral fat, more commonly called belly fat, is known to ... causes visceral fat to accumulate? The culprit is likely ... hormone balance that occurs during the menopause transition, according to ... factors we analyzed that could possibly account for the increase ...
Cached Biology News:10th Functional Genomics: Chemical Biology 2009 2Research supports calls to study health benefits of nitrate, nitrite 2Increase in visceral fat during menopause linked with testosterone 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
Biology Products: